A phase II dose-ranging study of palonosetron in Japanese patients receiving moderately emetogenic chemotherapy, including anthracycline and cyclophosphamide-based chemotherapy

Annals of Oncology

Volumn 20, Issue 11, 2009, Pages 1874-1880

  Segawa, Y ^a,j   Aogi, K ^a   Inoue, K ^b   Sano, M ^c   Sekine, I ^d   Tokuda, Y ^e   Isobe, H ^f   Ogura, T ^g   Tsuboi, M ^h   Atagi, S ⁱ  

^a NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^b SAITAMA CANCER CENTER   (Japan)

^c Niigata Cancer Center   (Japan)

^d NATIONAL CANCER CENTER HOSPITAL   (Japan)

^e TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f HOKKAIDO CANCER CENTER   (Japan)

^g Kanagawa Prefectural Cardiovascular and Respiratory Diseases Center Hospital   (Japan)

^h TOKYO MEDICAL UNIVERSITY   (Japan)

ⁱ NATIONAL HOSPITAL ORGANIZATION KINKI CHUO CHEST MEDICAL CENTER   (Japan)

^j NATIONAL SANYO HOSPITAL   (Japan)

more..

Author keywords

5 HT3 receptor antagonist; Chemotherapy induced nausea and vomiting; Palonosetron

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIPHENHYDRAMINE; DOXORUBICIN; EPIRUBICIN; FAMOTIDINE; PACLITAXEL; PALONOSETRON; RANITIDINE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANAPHYLAXIS; ARTICLE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONSTIPATION; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERBILIRUBINEMIA; JAPAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEOPLASM; OPTIMAL DRUG DOSE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT;

EID: 71049160391     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp243     Document Type: Article

References (23)

1. Bloechl-Daum B, Deuson RR, Mavros P et al. Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 2006; 24: 4472-4478.
2. Cooper S, Georgiou V. The impact of cytotoxic chemotherapy - perspectives from patients, specialists and nurses. Eur J Cancer 1992; 28A (Suppl 1): S36-S38.
3. Berger AM, Clark-Snow RA. Adverse effects of treatment: Nausea and vomiting. In DeVita VT Jr, Hellman S, Rosenberg SA (eds), Cancer: Principles and Practice of Oncology, 5th edition. Philadelphia, PA: Lippincott-Raven 1997; 2705-2714.
4. The Italian Group for Antiemetic Research. Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy. N Engl J Med 2000; 342: 1554-1559.
5. Kaizer L, Warr D, Hoskins P et al. Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: A phase III trial by the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1994; 12: 1050-1057.
6. Osoba D, Zee B, Pater J et al. Determinants of postchemotherapy nausea and vomiting in patients with cancer. Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1997; 15: 116-123.
7. Geling O, Eichler HG. Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol 2005; 23: 1289-1294.
8. Hickok JT, Roscoe JA, Morrow GR et al. 5-Hydroxytryptamine-receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: A URCC CCOP randomised controlled trial. Lancet Oncol 2005; 6: 765-772.
9. Wong EH, Clark R, Leung E et al. The interaction of RS 25259-197, a potent and selective antagonist, with 5-HT3 receptors, in vitro. Br J Pharmacol 1995; 114: 851-859.
10. Piraccini G, Stolz R, Tei M, Macciocchi A. Pharmacokinetic features of a novel 5-HT3-receptor-antagonist: Palonosetron (RS-25259-197). J Clin Oncol 2001; 20: 400a.
11. Kees F, Farber L, Bucher M et al. Pharmacokinetics of therapeutic doses of tropisetron in healthy volunteers. Br J Clin Pharmacol 2001; 52: 705-707.
12. McNulty R. Are all 5-HT3 receptor antagonists the same? J Natl Compr Canc Netw 2007; 5: 35-43.
13. Aapro MS, Grunberg SM, Manikhas GM et al. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 2006; 17: 1441-1449.
14. Eisenberg P, Figueroa-Vadillo J, Zamora R et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer 2003; 98: 2473-2482.
15. Gralla R, Lichinitser M, Van Der Vegt S et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: Results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 2003; 14: 1570-1577.
16. Eisenberg P, MacKintosh FR, Ritch P et al. Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: A dose-ranging clinical study. Ann Oncol 2004; 15: 330-337.
17. Ettinger DS, Bierman PJ, Bradbury B et al. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology - v.1.2004 Antiemesis; http://www.nccn.org/professionals/physician_gls/PDF/antiemesis.pdf (July 2009 date last accessed).
18. Cockcroft D. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
19. Bookman MA, Kloth DD, Kover PE et al. Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions. Ann Oncol 1997; 8: 611-614.
20. Ioannidis JP, Hesketh PJ, Lau J. Contribution of dexamethasone to control of chemotherapy-induced nausea and vomiting: A meta-analysis of randomized evidence. J Clin Oncol 2000; 18: 3409-3422.
21. Kris MG, Hesketh PJ, Somerfield MR et al. American Society of Clinical Oncology guideline for antiemetics in oncology: Update 2006. J Clin Oncol 2006; 24: 2932-2947.
22. Ettinger DS, Bierman PJ, Bradbury B et al. Antiemesis. J Natl Compr Canc Netw 2007; 5: 12-33.
23. Masuda N, Sekine I, Kubota K et al. A phase II dose-response study of palonosetron (PALO) in Japanese patients receiving highly emetogenic chemotherapy (HEC) - Palo Japanese Cooperative Study Group. Ann Oncol 2006; 17 (Suppl 9): Ix303.